Class Action Filed Against Biohaven Ltd. and Its Officers for Securities Fraud
On July 17, 2025, Pomerantz LLP announced the initiation of a class action lawsuit filed against Biohaven Ltd. (NYSE: BHVN) alongside certain of its officers. This lawsuit, which is recorded under docket number 25-cv-01120 in the United States District Court for the District of Connecticut, represents all individuals and entities, excluding the defendants, who acquired Biohaven securities from March 24, 2023, to May 14, 2025. The goal of the plaintiffs is to recover damages caused due to alleged violations of federal securities laws by the company and its key personnel.
If you participated in purchasing Biohaven securities during the stated period, you have until September 12, 2025, to request that the court appoint you as the Lead Plaintiff for the group. Individuals interested can obtain a copy of the complaint at www.pomerantzlaw.com. Interested parties may reach out to Danielle Peyton via email at [email protected] or call at 646-581-9980. Those inquiring through email are advised to include their mailing address, phone number, and details about the shares acquired.
Biohaven is a biopharmaceutical firm devoted to the research, development, and commercialization of therapies in fields such as immunology, neuroscience, and oncology. Notable among its product candidates is troriluzole, aimed at treating spinocerebellar ataxia (SCA), and BHV-7000, targeting bipolar disorder.
In May 2022, a Phase 3 trial assessing the effectiveness of troriluzole for SCA failed to meet its primary endpoint, however, Biohaven's executives continued to promote the drug's viability and regulatory outlook, citing subsequent analyses and additional data. In May 2023, the firm declared that it had filed a New Drug Application (NDA) with the FDA for troriluzole as a treatment for SCA. Subsequently, in October 2023, Biohaven disclosed that its Marketing Authorization Application (MAA) for the same treatment had been accepted by the European Medicines Agency (EMA).
The lawsuit claims that during the Class Period, Biohaven's executives made materially misleading statements regarding the company’s operations and projections. These claims include overstating the regulatory prospects of troriluzole as well as the sufficiency of data submitted to aid in its approval. Moreover, statements regarding BHV-7000's efficacy were also alleged to be exaggerated.
On July 27, 2023, Biohaven revealed that the FDA had denied its NDA for troriluzole, refusing to assess the application due to the earlier failure of the Phase 3 trial. Following this announcement, Biohaven's stock plummeted by over 22%, representing a significant financial blow to its investors.
Subsequent disclosures from Biohaven indicated ongoing struggles; on March 3, 2025, the company admitted that the data from a late-stage study of BHV-7000 in bipolar mania did not meet statistical significance, resulting in another decline in stock price by approximately 13.77%.
Further compounding issues, news emerged that Biohaven had withdrawn its MAA for troriluzole in late March 2025, invoking another wave of declines in its stock price. This downward trend continued when on May 14, 2025, the firm issued a release indicating delays from the FDA concerning their NDA review due to ongoing assessments of new data.
Despite these hurdles, Pomerantz LLP, with a legacy established by the late Abraham L. Pomerantz, has remained a leading firm in corporate, securities, and antitrust litigation. For over 85 years, they have fought relentlessly for the rights of those impacted by securities fraud, and have facilitated the recovery of billions of dollars for class members.
For more information on the class action or how to participate, please contact Pomerantz LLP. The firm underscores that prior results do not guarantee similar outcomes, and the legal battle is just beginning for those affected by these alleged wrongdoings.
If you participated in purchasing Biohaven securities during the stated period, you have until September 12, 2025, to request that the court appoint you as the Lead Plaintiff for the group. Individuals interested can obtain a copy of the complaint at www.pomerantzlaw.com. Interested parties may reach out to Danielle Peyton via email at [email protected] or call at 646-581-9980. Those inquiring through email are advised to include their mailing address, phone number, and details about the shares acquired.
Biohaven is a biopharmaceutical firm devoted to the research, development, and commercialization of therapies in fields such as immunology, neuroscience, and oncology. Notable among its product candidates is troriluzole, aimed at treating spinocerebellar ataxia (SCA), and BHV-7000, targeting bipolar disorder.
In May 2022, a Phase 3 trial assessing the effectiveness of troriluzole for SCA failed to meet its primary endpoint, however, Biohaven's executives continued to promote the drug's viability and regulatory outlook, citing subsequent analyses and additional data. In May 2023, the firm declared that it had filed a New Drug Application (NDA) with the FDA for troriluzole as a treatment for SCA. Subsequently, in October 2023, Biohaven disclosed that its Marketing Authorization Application (MAA) for the same treatment had been accepted by the European Medicines Agency (EMA).
The lawsuit claims that during the Class Period, Biohaven's executives made materially misleading statements regarding the company’s operations and projections. These claims include overstating the regulatory prospects of troriluzole as well as the sufficiency of data submitted to aid in its approval. Moreover, statements regarding BHV-7000's efficacy were also alleged to be exaggerated.
On July 27, 2023, Biohaven revealed that the FDA had denied its NDA for troriluzole, refusing to assess the application due to the earlier failure of the Phase 3 trial. Following this announcement, Biohaven's stock plummeted by over 22%, representing a significant financial blow to its investors.
Subsequent disclosures from Biohaven indicated ongoing struggles; on March 3, 2025, the company admitted that the data from a late-stage study of BHV-7000 in bipolar mania did not meet statistical significance, resulting in another decline in stock price by approximately 13.77%.
Further compounding issues, news emerged that Biohaven had withdrawn its MAA for troriluzole in late March 2025, invoking another wave of declines in its stock price. This downward trend continued when on May 14, 2025, the firm issued a release indicating delays from the FDA concerning their NDA review due to ongoing assessments of new data.
Despite these hurdles, Pomerantz LLP, with a legacy established by the late Abraham L. Pomerantz, has remained a leading firm in corporate, securities, and antitrust litigation. For over 85 years, they have fought relentlessly for the rights of those impacted by securities fraud, and have facilitated the recovery of billions of dollars for class members.
For more information on the class action or how to participate, please contact Pomerantz LLP. The firm underscores that prior results do not guarantee similar outcomes, and the legal battle is just beginning for those affected by these alleged wrongdoings.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.